Lesson plan

NS-11821

NS-11821, or NS11821 is a GABA A receptor positive allosteric modulator and nonbenzodiazepine which was under development for the treatment of anxiety disorders and CNS disorders but was never marketed. It is taken orally. The drug is a subunit-selective partial positive allosteric modulator of the GABA A receptor. More specifically, it shows affinity (K i ) values of 1.6 nM at α 1 , 9.7 nM at α 2 , 3.8 nM at α 3 , and 2.5 nM at α 5 , whereas it shows ( ) values of (4%) at α 1 , 59 nM (17%) at α 2 , 73 nM (40%) at α 3 , and 44 nM (41%) at α 5 . Based on animal studies, this is expected to translate into a profile of anxiolytic effects with low propensity for sedation. Clinical findings of NS-11821 in humans have been described. NS-11821 was under development by NeuroSearch. It reached phase 1 clinical trials for both anxiety disorders and CNS disorders prior to the discontinuation of its development in 2017. The chemical structure of NS-11821 does not yet appear to have been disclosed.

Back to article

Article summary

NS-11821, or NS11821 is a GABA A receptor positive allosteric modulator and nonbenzodiazepine which was under development for the treatment of anxiety disorders and CNS disorders but was never marketed. It is taken orally. The drug is a subunit-selective partial positive allosteric modulator of the GABA A receptor. More specifically, it shows affinity (K i ) values of 1.6 nM at α 1 , 9.7 nM at α 2 , 3.8 nM at α 3 , and 2.5 nM at α 5 , whereas it shows ( ) values of (4%) at α 1 , 59 nM (17%) at α 2 , 73 nM (40%) at α 3 , and 44 nM (41%) at α 5 . Based on animal studies, this is expected to translate into a profile of anxiolytic effects with low propensity for sedation. Clinical findings of NS-11821 in humans have been described. NS-11821 was under development by NeuroSearch. It reached phase 1 clinical trials for both anxiety disorders and CNS disorders prior to the discontinuation of its development in 2017. The chemical structure of NS-11821 does not yet appear to have been disclosed.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.